**GLP-1R agonists** and **sulthiame** show promise for **Obstructive Sleep Apnea** in older adults.

Obstructive Sleep Apnea (OSA) is highly prevalent in older adults, yet diagnosis is challenging due to less severe symptoms and poor screening tool specificity. The current standard, Continuous Positive Airway Pressure (CPAP), often faces patient refusal and unclear benefits in this population. This creates a significant gap in effective, tolerable management strategies. Understanding the pathophysiology of OSA has revealed several pharmacologic targets, offering a potential alternative to mechanical ventilation and addressing the unique needs of older patients who may be more susceptible to adverse effects from certain drug classes.

This review synthesized emerging research on pharmacologic treatments for Obstructive Sleep Apnea (OSA), specifically focusing on older adults. The authors evaluated various drug classes based on their unique mechanisms, reported efficacy, and safety/tolerability profiles relevant to an aging population. The analysis considered agents targeting upper airway adiposity, pharyngeal dilator tone, sleep quality, and arousal thresholds. The review aimed to identify promising therapeutic avenues and highlight considerations for age-specific diagnostic and management strategies in OSA.